{"entity":{"id":"dt-9081","kind":"drug","name":"DT-9081","aka":[],"tldr":"DT-9081 is an experimental oral small molecule from Domain Therapeutics, in phase 1 trials for advanced solid tumours.","summary":"DT-9081 is an oral small molecule (receptor antagonist) from Domain Therapeutics. An oral EP4 receptor antagonist designed to reverse the immune suppression caused by prostaglandin E2 made by COX-2-positive tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 EPRAD (NCT05582850) terminated at the end of dose escalation, \"based on Sponsor's strategic decision\"; the company still lists DT-9081 as \"Phase II-ready\". Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Domain Therapeutics: kainovatx.com","url":"https://www.kainovatx.com/"},{"label":"Domain Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05582850"},{"label":"ClinicalTrials.gov: trials of DT-9081","url":"https://clinicaltrials.gov/search?intr=DT-9081"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["domain-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05582850"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DT-9081","modality":"Oral small molecule (receptor antagonist)","mechanism":"An oral EP4 receptor antagonist designed to reverse the immune suppression caused by prostaglandin E2 made by COX-2-positive tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dt-9081/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"domain-therapeutics","kind":"company","name":"Kainova Therapeutics","route":"/companies/domain-therapeutics/"}],"trial":[{"id":"nct05582850","kind":"trial","name":"DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours","route":"/trials/nct05582850/"}],"target":[{"id":"ep4","kind":"target","name":"EP4 (PTGER4)","route":"/targets/ep4/"}]}}